Targeting Adolescent Insomnia to Lessen Overall Risk of Suicidal Behavior
NCT05390918 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 235
Last updated 2026-02-05
Summary
This study will test the effectiveness of a sleep-related primary suicide prevention program entitled TAILOR (Targeting Adolescent Insomnia to Lessen Overall Risk of Suicidal Behavior), which includes specific behavior-change strategies for adolescents at risk of suicidal behavior who suffer from difficulties falling asleep, staying asleep, and/or insufficient sleep.
Conditions
- Insomnia
- Suicidal Ideation
- Suicide, Attempted
Interventions
- BEHAVIORAL
-
TAILOR
The first TAILOR session will assess existing sleep problems from both the adolescent's and parent/legal guardian's perspectives, concluding with offering a CBT strategy to try. Session 2 will involve getting feedback from the family on that specific strategy and then offering additional CBT strategies. The remaining sessions will be devoted to refining the use of CBT strategies. MI will be integrated as the communication style throughout, including reflective listening, rolling with resistance, and showing deference to the family's ultimate decisions. The interventionist will also use the "elicit-provide-elicit" approach from MI. The interventionist will elicit the family's own ideas for improving the adolescent's sleep, ask for permission to provide his/her own suggestions, and then gauge the family's reactions to those suggestions, versus simply recommending a CBT strategy and problem-solving barriers to implementation.
- OTHER
-
Enhanced Usual Care
The study clinician will conduct suicide risk screening and further assessment and safety planning where deemed necessary.
Sponsors & Collaborators
-
Centers for Disease Control and Prevention
collaborator FED -
Jeff Bridge
lead OTHER
Principal Investigators
-
Jeff Bridge, Ph.D. · Nationwide Children's Hospital
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 11 Years
- Max Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-10-20
- Primary Completion
- 2027-02-28
- Completion
- 2027-02-28
Countries
- United States
Study Locations
More Related Trials
-
Efficacy and Safety Assessment of ZOlpidem (Stilnox CR) in Patients With Chronic insomNIA
NCT01024192 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics (PK) of Oral TAK-994 in an Acute Sleep Phase Delay Paradigm in Healthy Male Participants
NCT04551079 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy of Sleeping Without Pills (SWOP), an Online Drug Tapering Program
NCT03194802 ·Status: COMPLETED ·Phase: NA
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of TAK-925 Study in Sleep-Deprived Healthy Adults
NCT03522506 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia
NCT06953869 ·Status: RECRUITING ·Phase: PHASE3
-
Solriamfetol and CBT-I in Patients With Insomnia Disorder
NCT05838430 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Efficacy of Chronic Hypnotic Use
NCT01006525 ·Status: COMPLETED
-
Evaluation of the Efficacy and Safety of Subcutaneous Ketamine in the Treatment of Depressive Episode With Suicidal Ideation and/or Behavior in Adolescents
NCT06957704 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Feasibility Study of Personalized Trials to Improve Sleep Quality
NCT05349188 ·Status: COMPLETED ·Phase: PHASE1
-
A Long Term Safety Study of Suvorexant in Participants With Primary Insomnia (MK-4305-009 AM3)
NCT01021813 ·Status: COMPLETED ·Phase: PHASE3
-
Long-Term Efficacy of Ramelteon on Endocrine Function in Adult Subjects With Chronic Insomnia
NCT00656994 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of JNJ-404118413 in Healthy Male Patients
NCT01951053 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Tolerability of Tasipimidine in Sleepless Patients
NCT06956495 ·Status: COMPLETED ·Phase: PHASE2
-
Safety, Tolerability and Efficacy Study of V117957 in Subjects With Insomnia Associated With Alcohol Cessation
NCT04035200 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Safety and Efficacy of BTD-001 in Treatment of Patients With Idiopathic Hypersomnia (IH) or Narcolepsy Type 2
NCT02512588 ·Status: COMPLETED ·Phase: PHASE2
-
Insomnia and Drug Relapse Risk
NCT00253890 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Zolpidem Tartrate Sublingual Tablet in Adult Patients With Insomnia
NCT00380081 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy of Melatonin, Low-dose Quetiapine, or Placebo in Patients With Psychiatric Disorders and Comorbid Insomnia
NCT06062953 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Zolpidem (Myslee) Post Marketing Study in Adolescent Patients With Insomnia - Evaluation With Polysomnography
NCT00653562 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Investigate The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JZP441 in Sleep-deprived Healthy Participants
NCT05651152 ·Status: COMPLETED ·Phase: PHASE1
-
6-Month Chronic Efficacy & Safety Study of Eszopiclone in Adult Subjects With Primary Insomnia
NCT00352144 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety Study of Org 50081 (Esmirtazapine) in Elderly Participants (P05709)
NCT00561821 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy of Mobile-delivered Sleep Restriction Therapy for Treatment of Insomnia Disorder: Randomised Controlled Trial
NCT06114901 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
A Double-blind, Parallel Group, Placebo-Controlled Outpatient Trial of PD 00200390 in Adults With Nonrestorative Sleep
NCT00655369 ·Status: COMPLETED ·Phase: PHASE2
-
Melatonin Treatment for Induced Transient Insomnia
NCT00950885 ·Status: COMPLETED ·Phase: NA